| Autor: |
Yang JL; Research Center of Clinical Medicine, Affiliated Hospital & Department of Immunology, Medical School, Nantong University, Nantong 226001, China., Fang RF; Department of Gastrenterology, Affiliated Hospital of Nantong University, Nantong 226001, China., Xie Q; Department of Infectious Diseases, Haian People's Hospital, Haian 226600, China., Tai BJ; Department of Infectious Diseases, Affiliated Hospital of Nantong University, Nantong 226001, China., Yao DF; Research Center of Clinical Medicine, Affiliated Hospital & Department of Immunology, Medical School, Nantong University, Nantong 226001, China Department of Gastrenterology, Affiliated Hospital of Nantong University, Nantong 226001, China., Yao M; Research Center of Clinical Medicine, Affiliated Hospital & Department of Immunology, Medical School, Nantong University, Nantong 226001, China. |
| Abstrakt: |
Objective: To analyze and evaluate the expressions and clinical value of tuftelin (TUFT1) and Krüppel-like factor 5 (KLF5) in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) tissues. Method: KLF5 mRNA and TUFT1 mRNA transcriptional status in cancer and non-cancer groups were compared according to the Cancer Genome Atlas (TCGA) database. The differences and prognostic value between the groups were analyzed. Postoperative liver cancer and its paired pericancerous tissues, with the approval of the ethics committee, were collected to build tissue chips. The expression of KLF5 and TUFT1 and their intracellular localization were verified by immunohistochemistry. Tissue expression and clinicopathological characteristics were analyzed by immunoblotting. SPSS software was used to analyze the relationship between SPSS and patient prognosis. Results: The transcription level of TUFT1 or KLF5 mRNA was significantly higher in the HCC group than the non-cancer group ( P < 0.001), according to TCGA data. Immunohistochemistry and Western blotting examination confirmed the overexpression of TUFT1 and KLF5 in human HCC tissues, which were mainly localized in the cytoplasm and cell membrane. The positivity rates of TUFT1 and KLF5 were 87.1% ( χ (2) = 18.563, P < 0.001) and 95.2% ( χ (2) = 96.435, P < 0.001) in HCC tissues, and both were significantly higher than those in the adjacent group. The expression intensity was higher in stage III-IV than stage I-II of the International Union Against Cancer standard ( P < 0.01). The clinicopathological features showed that the abnormalities of the two were significantly related to HBV infection, tumor size, extrahepatic metastasis, TNM stage, and ascites. Univariate analysis was related to tumor size, HBV infection, and survival. Multivariate analysis was an independent prognostic factor for patients with HCC. Conclusion: TUFT1 and KLF5 may both be novel markers possessing clinical value in the diagnosis and prognosis of HBV-related HCC. |
